Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
house dust mite sublingual drops
- Development stage
- Unknown
- Lead developer
- Wolwo Biotech
- Modality
- Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Sublingual
01
Overview
House dust mite sublingual drops refer to a class of allergen immunotherapy (AIT) products containing standardized extracts of house dust mites, most commonly *Dermatophagoides farinae* and *Dermatophagoides pteronyssinus*. These products are administered sublingually to induce immunological tolerance in patients suffering from allergic rhinitis, allergic asthma, or atopic dermatitis. The mechanism of action involves the modulation of the immune system's response to mite allergens, specifically by promoting the expansion of regulatory T cells (Tregs) and shifting the cytokine profile from a pro-inflammatory Th2 response toward a Th1-mediated regulatory profile. This shift leads to a reduction in allergen-specific IgE levels and a decrease in the recruitment of inflammatory cells like eosinophils and mast cells to the target tissues. A prominent example in the Chinese market is the *Dermatophagoides farinae* drops (brand name Chan Di) developed by Zhejiang Wolwo Bio-Pharmaceutical, which has been investigated in Phase II trials for the treatment of atopic dermatitis and is already approved for allergic rhinitis and asthma.
- Brand names
- Chan DiChangdi
- Other names
- house dust mite sublingual dropsDermatophagoides farinae dropsHDM SLIThouse dust mite allergen extract
02
Targets
T-cell receptor specific for Dermatophagoides farinae allergensHouse dust mite-specific B-cell receptor
Beyond the preview
Go deeper on house dust mite sublingual drops.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on house dust mite sublingual drops.